ES2167427T3 - Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca. - Google Patents
Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca.Info
- Publication number
- ES2167427T3 ES2167427T3 ES95914882T ES95914882T ES2167427T3 ES 2167427 T3 ES2167427 T3 ES 2167427T3 ES 95914882 T ES95914882 T ES 95914882T ES 95914882 T ES95914882 T ES 95914882T ES 2167427 T3 ES2167427 T3 ES 2167427T3
- Authority
- ES
- Spain
- Prior art keywords
- growth
- mammal
- combination
- insulin
- hormone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 5
- 102000018997 Growth Hormone Human genes 0.000 abstract 3
- 108010051696 Growth Hormone Proteins 0.000 abstract 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 3
- 239000000122 growth hormone Substances 0.000 abstract 3
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 230000002107 myocardial effect Effects 0.000 abstract 2
- 239000005541 ACE inhibitor Substances 0.000 abstract 1
- 102000013275 Somatomedins Human genes 0.000 abstract 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fodder In General (AREA)
Abstract
SE MUESTRAN METODOS PARA MEJORAR LA CONTRACTIBILIDAD MIOCARDICA Y EL RENDIMIENTO CARDIACO EN UN MAMIFERO CON FALLO CARDIACO CONGESTIVO. EN UN PRIMER METODO UN MAMIFERO CON FALLO CARDIACO CONGESTIVO SE TRATA CON LA ADMIMISTACION DE UNA CANTIDAD EFECTIVA DE LA COMBINACION DE HORMONA DE CRECIMIENTO (GH) Y EL FACTOR DE CRECIMIENTO INSULINOIDE (IGF-I). UN SEGUNDO METODO CONSISTE EN LA ADMINISTRACION AL MAMIFERO DE UNA CANTIDAD EFECTIVA DE UNA COMBINACION DE GH E IGF-I EN PRESENCIA DE UN INHIBIDOR ACE. ESTE METODO DA LUGAR A UNA MEJORA DE LA CONTRACTILIDAD MIOCARDICA Y DEL RENDIMIENTO CARDIACO SOBRE EL NIVEL CONSEGUIDO CON LA INHIBICION ACE SOLA. PREFERIBLEMENTE, EL MAMIFERO ES UN SER HUMANO.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22792394A | 1994-04-15 | 1994-04-15 | |
| US08/284,859 US5661122A (en) | 1994-04-15 | 1994-08-02 | Treatment of congestive heart failure |
| US08/333,909 US5610134A (en) | 1994-04-15 | 1994-11-03 | Treatment of congestive heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2167427T3 true ES2167427T3 (es) | 2002-05-16 |
Family
ID=27397790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95914882T Expired - Lifetime ES2167427T3 (es) | 1994-04-15 | 1995-03-30 | Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5610134A (es) |
| EP (1) | EP0755265B1 (es) |
| JP (1) | JP3473623B2 (es) |
| AT (1) | ATE208209T1 (es) |
| AU (1) | AU691273B2 (es) |
| CA (1) | CA2185998C (es) |
| DE (1) | DE69523747T2 (es) |
| DK (1) | DK0755265T3 (es) |
| ES (1) | ES2167427T3 (es) |
| HK (1) | HK1003418A1 (es) |
| LV (1) | LV12966B (es) |
| PT (1) | PT755265E (es) |
| WO (1) | WO1995028174A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3182307B2 (ja) * | 1994-12-27 | 2001-07-03 | 株式会社荏原製作所 | 全周流型ポンプ |
| US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| WO1997034604A1 (en) * | 1996-03-21 | 1997-09-25 | Merck & Co., Inc. | 4-spiroindoline piperidines promote release of growth hormone |
| US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
| US6015384A (en) * | 1998-08-31 | 2000-01-18 | Acuson Corporation | Ultrasonic system and method for tissue viability imaging |
| SE9901634D0 (sv) * | 1999-05-05 | 1999-05-05 | Sahltech Ab | Treatment of myocardial infarction with a substance related to the growth hormone axis |
| ES2300268T3 (es) * | 1999-07-12 | 2008-06-16 | Sandoz Ag | Formulaciones de las hormonas de crecimiento. |
| DK1196186T3 (da) * | 1999-07-12 | 2008-03-03 | Genentech Inc | Stimulering eller inhibering af angiogenese og kardiovaskularisation med tumornekrosefaktorligand/receptorhomologer |
| ATE440139T1 (de) | 2000-02-11 | 2009-09-15 | Genentech Inc | Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung |
| FR2805051B1 (fr) * | 2000-02-14 | 2002-12-06 | Geophysique Cie Gle | Methode de surveillance sismique d'une zone souterraine par utilisation simultanee de plusieurs sources vibrosismiques |
| EP2275549A1 (en) | 2000-06-23 | 2011-01-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| CA2648051A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US7862810B2 (en) | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| US20020061587A1 (en) | 2000-07-31 | 2002-05-23 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| US7547674B2 (en) * | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| US20030224984A1 (en) * | 2001-06-20 | 2003-12-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US6607517B1 (en) | 2001-08-24 | 2003-08-19 | Radiant Medical, Inc. | Method of inotropic treatment of heart disease using hypothermia |
| BR0317888A (pt) | 2002-12-31 | 2005-12-06 | Altus Pharmaceuticals Inc | Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos |
| EP1841443A4 (en) * | 2005-01-11 | 2012-05-02 | Heart Failure Technologies Inc | METHOD AND SYSTEM FOR TREATING HEART ERRORS |
| WO2009062143A2 (en) | 2007-11-09 | 2009-05-14 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof |
| US8512696B2 (en) | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
| CA2743698A1 (en) | 2007-11-30 | 2009-06-11 | New York Medical College | Compositions comprising vascular and myocyte progenitor cells and methods of their use |
| CA2743682A1 (en) | 2007-11-30 | 2009-06-11 | New York Medical College | Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| ES2084190T3 (es) * | 1990-10-25 | 1996-05-01 | Genentech Inc | Utilizacion de agentes protectores contra especies de oxigeno reactivas. |
| SE9100099D0 (sv) * | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
| SE9101840L (sv) * | 1991-06-14 | 1992-12-15 | Kabi Pharmacia | Ny medicinsk anvaendning |
| US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
| AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
-
1994
- 1994-11-03 US US08/333,909 patent/US5610134A/en not_active Expired - Lifetime
-
1995
- 1995-03-30 DE DE69523747T patent/DE69523747T2/de not_active Expired - Lifetime
- 1995-03-30 ES ES95914882T patent/ES2167427T3/es not_active Expired - Lifetime
- 1995-03-30 EP EP95914882A patent/EP0755265B1/en not_active Expired - Lifetime
- 1995-03-30 AU AU21956/95A patent/AU691273B2/en not_active Expired
- 1995-03-30 JP JP52697595A patent/JP3473623B2/ja not_active Expired - Lifetime
- 1995-03-30 AT AT95914882T patent/ATE208209T1/de active
- 1995-03-30 WO PCT/US1995/003755 patent/WO1995028174A1/en active IP Right Grant
- 1995-03-30 PT PT95914882T patent/PT755265E/pt unknown
- 1995-03-30 DK DK95914882T patent/DK0755265T3/da active
- 1995-03-30 CA CA2185998A patent/CA2185998C/en not_active Expired - Lifetime
-
1998
- 1998-03-24 HK HK98102461A patent/HK1003418A1/xx not_active IP Right Cessation
-
2002
- 2002-10-15 LV LVP-02-184A patent/LV12966B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU691273B2 (en) | 1998-05-14 |
| ATE208209T1 (de) | 2001-11-15 |
| EP0755265A1 (en) | 1997-01-29 |
| JP3473623B2 (ja) | 2003-12-08 |
| DE69523747D1 (de) | 2001-12-13 |
| US5610134A (en) | 1997-03-11 |
| CA2185998C (en) | 2011-02-22 |
| PT755265E (pt) | 2002-04-29 |
| EP0755265B1 (en) | 2001-11-07 |
| JPH09512008A (ja) | 1997-12-02 |
| CA2185998A1 (en) | 1995-10-26 |
| DK0755265T3 (da) | 2002-03-04 |
| LV12966B (en) | 2003-05-20 |
| WO1995028174A1 (en) | 1995-10-26 |
| HK1003418A1 (en) | 1998-10-30 |
| DE69523747T2 (de) | 2002-08-01 |
| AU2195695A (en) | 1995-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2167427T3 (es) | Combinacion de hormona de crecimiento y factor de crecimiento similar a insulina en el tratamiento de la insuficiencia cardiaca. | |
| ATE470448T1 (de) | Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid | |
| ATE390932T1 (de) | Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt | |
| MD1558F2 (en) | Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor | |
| PL338705A1 (en) | Application of gaba analogues in preventing and treating gastrointestinal diseases | |
| ATE433324T1 (de) | Verwendung von glp-1 oder analoge zur behandlung von schlaganfall | |
| BR9709068A (pt) | Processo de tratamento. | |
| AU2003291004A1 (en) | Stress reduction pacing mode for arrhythmia prevention | |
| RU2005102593A (ru) | Применение hmgb1 при лечении повреждения ткани и/или для промотирования восстановления ткани | |
| MX9301387A (es) | Metodo y composicion para el tratamiento de osteoporosis. | |
| PL329077A1 (en) | Method of treating cardiac insufficiency by means of endotelin antagonists | |
| MX9604803A (es) | Combinacion de hormona del crecimiento y factor de crecimiento similar a insulina para el tratamiento del fallo cardiaco congestivo. | |
| DE69110615T2 (de) | Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung. | |
| DE69305091T2 (de) | Methode zur behandlung oder verhütung von fettleibigkeit | |
| EA200000140A1 (ru) | Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы | |
| ATE239497T1 (de) | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen | |
| Numata et al. | Possible involvement of hypothyroidism as a cause of lithium‐induced sinus node dysfunction | |
| ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| DE60028750D1 (de) | Verwendung von tagatose zur verbesserung wichtiger blutfaktoren | |
| GEP19980848B (en) | Method for Treatment of Chronic Inflammatory Processes and Comlications Developed on its Bases | |
| RU94018734A (ru) | Способ сохранения парадонтозных и плоходержащихся (шатающихся) зубов | |
| DE50009220D1 (de) | Verwendung von moxonidin zur behandlung nach herzinfarkt | |
| RU99111444A (ru) | Способ заместительной терапии у мужчин с возрастным андрогенным дефицитом | |
| RU95116393A (ru) | Способ лечения заболеваний спинного мозга | |
| RU95116472A (ru) | Способ лечения системной склеродермии |